Pharma BD Deal Intelligence
AstraZeneca licensed global rights (ex-China) to ECC5004 from Eccogene in November 2023, an investigational oral once-daily small-molecule GLP-1 receptor agonist for obesity, type 2 diabetes and cardiometabolic conditions. Eccogene received $185M upfront with up to $1.825B in clinical, regulatory and commercial milestones plus tiered royalties. The asset, now named elecoglipron (AZD5004), has since de-risked materially: it advanced from Phase 1 at deal signing to two completed Phase 2b trials -- VISTA in obesity/overweight (NCT06579092, n=310, completed Nov 2025) and SOLSTICE in type 2 diabetes versus semaglutide and placebo (NCT06579105, n=406, completed Dec 2025). Per AstraZeneca's FY2025 results (Feb 2026), both trials met their primary endpoints, supporting progression to Phase 3, with full Phase 2 data presented at the ADA Scientific Sessions on 8 June 2026. The readouts validate the original thesis -- a differentiated oral small-molecule entry into the GLP-1 obesity/T2D race -- though detailed efficacy magnitude vs. Eli Lilly's orforglipron and Novo's oral semaglutide remained to be benchmarked at ADA.